ES2026198T3 - Compuesto a base de acido valproico solido, estable a la humedad y metodo para su preparacion. - Google Patents

Compuesto a base de acido valproico solido, estable a la humedad y metodo para su preparacion.

Info

Publication number
ES2026198T3
ES2026198T3 ES198787810611T ES87810611T ES2026198T3 ES 2026198 T3 ES2026198 T3 ES 2026198T3 ES 198787810611 T ES198787810611 T ES 198787810611T ES 87810611 T ES87810611 T ES 87810611T ES 2026198 T3 ES2026198 T3 ES 2026198T3
Authority
ES
Spain
Prior art keywords
weight
valproic acid
humidity
solid
stable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198787810611T
Other languages
English (en)
Inventor
Aracelis M. Dr. Ortega
Pilar Martin Dr. De Perez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FARVALSA AG
Original Assignee
FARVALSA AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FARVALSA AG filed Critical FARVALSA AG
Application granted granted Critical
Publication of ES2026198T3 publication Critical patent/ES2026198T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE PROPORCIONA UNA FORMULACION DE ACIDO VALPROICO SOLIDA, ESTABLE FRENTE A LA HUMEDAD, CAPAZ DE SER COMPRIMIDA A PASTILLAS. COMPRENDE: A) 55-65 % EN PESO DE ACIDO VALPROICO; B) 10-25 % EN PESO DE UNA CARGA POR LO MENOS; C) 10-20 % EN PESO DE UN DESINTEGRANTE POR LO MENOS; D) 3-6 % EN PESO DE UN LIGANTE POR LO MENOS; Y E) 0,5-1,2 % EN PESO DE UN LUBRICANTE POR LO MENOS. LA FORMULACION MAS PREFERIDA COMPRENDE; A) 60 (MAS MENOS) 5 % EN PESO DE ACIDO VALPROICO; B) 20 (MAS MENOS) 5 % EN PESO DE OXIDO MAGNESICO; C) 15 (MAS MENOS) 1 % EN PESO DE ALMIDON DE MAIZ; D1) 3 (MAS MENOS) 0,2 % EN PESO DE POLIVINILPIRROLIDONA; D2) 1 (MAS MENOS) 0,4 % EN PESO DE CARBOXIMETILCELULOSA SODICA; Y E) 1 (MAS MENOS) 0,2 % EN PESO DE ESTEARATO MAGNESICO.
ES198787810611T 1987-07-22 1987-10-23 Compuesto a base de acido valproico solido, estable a la humedad y metodo para su preparacion. Expired - Lifetime ES2026198T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7663487A 1987-07-22 1987-07-22

Publications (1)

Publication Number Publication Date
ES2026198T3 true ES2026198T3 (es) 1992-04-16

Family

ID=22133265

Family Applications (1)

Application Number Title Priority Date Filing Date
ES198787810611T Expired - Lifetime ES2026198T3 (es) 1987-07-22 1987-10-23 Compuesto a base de acido valproico solido, estable a la humedad y metodo para su preparacion.

Country Status (6)

Country Link
US (1) US5049586A (es)
EP (1) EP0300111B1 (es)
AT (1) ATE68346T1 (es)
DE (1) DE3773926D1 (es)
ES (1) ES2026198T3 (es)
GR (1) GR3003187T3 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR1002098B (en) * 1989-06-08 1995-12-28 Squibb & Sons Inc Pharmaceutical composition having good stability
US5629016A (en) * 1991-01-30 1997-05-13 Glaxo Wellcome Inc. Water-dispersible tablets
UA37214C2 (uk) * 1991-01-30 2001-05-15 Дзе Веллкам Фаундейшн Лімітед Таблетки, що диспергуються у воді, та спосіб їх виготовлення
GB9215908D0 (en) * 1992-07-27 1992-09-09 Wellcome Found Water dispersible tablets
US5698226A (en) * 1993-07-13 1997-12-16 Glaxo Wellcome Inc. Water-dispersible tablets
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
US20040191314A1 (en) * 1994-04-28 2004-09-30 Frank Jao Antiepileptic dosage form and process for protecting antiepileptic drug
US5681854A (en) * 1995-11-22 1997-10-28 Alcon Laboratories, Inc. Use of aliphatic carboxylic acid derivatives in ophthalmic disorders
CN1063971C (zh) * 1997-09-24 2001-04-04 中国兽药监察所 一种动物用冻干活疫苗制造方法
US6300328B1 (en) 1999-08-06 2001-10-09 Alcon Universal Ltd. Selective inhibitors of adenosine monophosphate deaminase for the treatment of optic nerve and retinal damage
WO2001043731A2 (en) * 1999-12-16 2001-06-21 Alcon, Inc. Inhibitors of adenosine kinase for the treatment of optic nerve and retinal damage
US20020143058A1 (en) 2001-01-24 2002-10-03 Taro Pharmaceutical Inductries Ltd. Process for preparing non-hygroscopic sodium valproate composition
US6610326B2 (en) * 2001-02-16 2003-08-26 Andrx Corporation Divalproex sodium tablets
US20040105886A1 (en) * 2001-02-16 2004-06-03 Chih-Ming Chen Divalproex sodium tablets
MXPA05005398A (es) 2002-11-22 2006-03-09 Univ Johns Hopkins Meta para terapia de deterioro cognitivo.
MXPA05005937A (es) 2002-12-06 2005-08-18 Alcon Inc Imitaciones de superoxido de dismutasa para el tratamiento de trastornos y enfermedades oculares.
US20040176463A1 (en) * 2003-02-05 2004-09-09 Daniella Licht Immediate release formulation of n-(2-propylpentanoyl)glycinamide
CN1889961A (zh) * 2003-12-11 2007-01-03 爱尔康公司 用于治疗视神经和视网膜损伤的超氧化物歧化酶拟似物
US20050276849A1 (en) * 2004-06-15 2005-12-15 Nilobon Podhipleux Sustained release dosage forms
US7713550B2 (en) * 2004-06-15 2010-05-11 Andrx Corporation Controlled release sodium valproate formulation
US20070048379A1 (en) * 2005-08-29 2007-03-01 Mintong Guo Valproate tablet
CA2635949A1 (en) * 2006-01-11 2007-07-19 Teva Pharmaceutical Industries Ltd. Controlled release formulation of divalproic acid and its derivatives
US20070160667A1 (en) * 2006-01-11 2007-07-12 Nava Shterman Controlled release formulation of divalproex sodium
ES2317450T3 (es) * 2006-01-11 2009-04-16 Teva Pharmaceutical Industries Ltd. Formulacion de liberacion controlada de acido valproico y sus derivados.
US7625927B2 (en) * 2006-02-27 2009-12-01 Alcon Research, Ltd. Method of treating glaucoma
WO2008001151A1 (en) * 2006-06-29 2008-01-03 Wockhardt Limited Controlled release compositions of divalproex sodium
CA2716124A1 (en) * 2008-02-20 2009-08-27 Boehringer Ingelheim International Gmbh Powder inhalers
US20090235929A1 (en) * 2008-03-19 2009-09-24 Marc Egen Powder inhalers
EP2346500B1 (en) 2008-10-16 2017-05-17 The Johns Hopkins University Methods and compositions for improving cognitive function
EP2533645B1 (en) * 2010-02-09 2016-07-27 The Johns Hopkins University Methods and compositions for improving cognitive function
PL2683371T3 (pl) * 2011-03-09 2021-04-19 Cereno Scientific Ab Związki i sposoby poprawy zaburzonej funkcji wewnątrzustrojowej fibrynolizy przy zastosowaniu inhibitorów deacetylazy histonowej
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
CA2904767C (en) 2013-03-15 2022-06-21 Agenebio, Inc. Methods and compositions for improving cognitive function
US10806717B2 (en) 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function
GB201417828D0 (en) 2014-10-08 2014-11-19 Cereno Scient Ab New methods and compositions
EA034167B8 (ru) 2015-05-22 2021-04-27 Эйджинбайо, Инк. Фармацевтические композиции леветирацетама пролонгированного высвобождения
US11395808B2 (en) 2016-04-08 2022-07-26 Cereno Scientific Ab Delayed release pharmaceutical formulations comprising valproic acid, and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL32673A (en) * 1968-08-05 1973-11-28 Ciba Geigy Ag A granular material containing oily or liquid therapeutically usable furanosides and a process for its manufacture
US4301176A (en) * 1980-08-18 1981-11-17 Warner-Lambert Company Method of administering calcium valproate
NL8600050A (nl) * 1986-01-13 1987-08-03 Sanico Nv Farmaceutisch preparaat met vertraagde afgifte van het werkzame bestanddeel en werkwijze voor de bereiding er van.

Also Published As

Publication number Publication date
DE3773926D1 (de) 1991-11-21
US5049586A (en) 1991-09-17
GR3003187T3 (en) 1993-02-17
EP0300111A1 (en) 1989-01-25
EP0300111B1 (en) 1991-10-16
ATE68346T1 (de) 1991-11-15

Similar Documents

Publication Publication Date Title
DE3773926D1 (de) Feuchtigkeitsstabile feste valproinsaeure-zubereitung und verfahren zu ihrer herstellung.
AU560829B2 (en) Continuous release pharmaceutical compositions
ES2042541T4 (es) Un procedimiento de preparacion de una formulacion farmaceutica de liberacion retardada que contiene goma de xantano.
GB2186485B (en) Slow release formulation
DE3583799D1 (de) Feste zubereitung mit langsamer freisetzung.
AU3183389A (en) Human relaxin formulation
IL74707A (en) Anti-viral compositions comprising pyridazinamines,certain such novel compounds and their preparation
EP0232849A3 (en) Pyrrolidineamide derivative of acylamino acid, pharmaceutical composition and use
LU90806I2 (fr) Ovidrelle-choriogonadotropine alfa et ses d-riv-s pharmaceutiquement acceptables
ES478687A1 (es) Un procedimiento para la preparacion de derivados de acido carbamico.
ZA79145B (en) Novel substituted n-phenyl-n'-(2-chloro-6-fluoro-benzoyl)-ureas,processes for their preparation and their use as insecticides
ATE135578T1 (de) Verbesserung reproduktiver funktionen bei säugern
DE68909958D1 (de) Phenoxyessigsäure-Derivate, ihre Herstellung, pharmazeutische Zusammensetzungen, die sie enthalten, und deren Verwendung.
EP0237241A3 (en) Calcium supplement compressed tablets
ATE63057T1 (de) Organophilen ton enthaltendes kompaktpulver sowie verfahren zu dessen herstellung.
ES2080132T3 (es) Procedimiento para la insolubilizacion y la aglomeracion de cenizas volantes de incineracion.
IS3359A7 (is) ""2-guanidino-thiazol", aðferð til framleiðslu þess og notkun sem milliafurð við framleiðslu "famotidine" (N-sulfamyl-3-[(2-guanidinothiazol-4-yl)methylthio] -propionamidine)"
BR8706991A (pt) Produto antitranspirante solido e processo para sua fabricacao
ES2014518A6 (es) Procedimiento para la produccion de una composicion farmaceutica de liberacion retardada.
ES8800217A1 (es) Procedimiento para la preparacion de acidos 4-(isoxazolil)-tiazol-2-oxamicos y sus derivados
IT1231723B (it) Derivati dell'acido piroglutammico, loro preparazioni e composizioni farmaceutiche che li contengono
EP0218953A3 (en) Derivatives of 19,20-bis-nor-prostanoic acid with antiulcer and anorectic activity, process for their preparation and pharmaceutical compositions thereof
DE3563416D1 (en) Hexetidin-containing therapeutically active agent, method for its preparation and its use as a vaginal disinfectant
IL80300A (en) Mitogenic tetradecapeptide homologs of human thrombin b
KR880012498A (ko) 전기광학용 투명 세라믹의 제조방법

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 300111

Country of ref document: ES